NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis $39.84 -1.33 (-3.23%) Closing price 04:00 PM EasternExtended Trading$40.12 +0.28 (+0.70%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nektar Therapeutics Stock (NASDAQ:NKTR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nektar Therapeutics alerts:Sign Up Key Stats Today's Range$39.26▼$40.9850-Day Range$39.91▼$76.4852-Week Range$33.40▼$109.00Volume1.05 million shsAverage Volume1.10 million shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$130.67Consensus RatingModerate Buy Company Overview Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that use the body’s immune system to treat cancer and autoimmune diseases. The company’s research programs are based on proprietary drug-design and immunology technologies intended to improve the activity, targeting, or dosing of therapeutic agents. Nektar’s pipeline has included NKTR-255, an investigational interleukin-15 receptor agonist designed to activate natural killer cells and support antitumor immune responses. The company has also developed rezpegaldesleukin, an investigational therapy intended to selectively expand regulatory T cells for the treatment of autoimmune and inflammatory diseases. These and other candidates remain subject to clinical testing and regulatory review. Founded in 1990 and headquartered in San Francisco, Nektar has historically used partnerships with larger pharmaceutical companies to advance and commercialize products based on its technology. Its earlier portfolio and collaborations included medicines such as Movantik, a treatment for opioid-induced constipation, as well as other products using the company’s polymer-conjugation and drug-delivery expertise. Nektar’s research and clinical activities serve patients and healthcare markets internationally. Howard W. Robin has served as Nektar Therapeutics’ president and chief executive officer. The company’s operations are primarily centered on research, clinical development, and strategic collaborations in oncology and immunology.AI Generated. May Contain Errors. Read More Nektar Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreNKTR MarketRank™: Nektar Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 350th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingNektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 1 strong buy rating, 10 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialNektar Therapeutics has a consensus price target of $130.67, representing about 228.0% upside from its current price of $39.84.Amount of Analyst CoverageNektar Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nektar Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nektar Therapeutics are expected to decrease in the coming year, from ($8.16) to ($10.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -5.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 9.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nektar Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.93% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 3.76, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nektar Therapeutics has recently increased by 21.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.52 News SentimentNektar Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Nektar Therapeutics this week, compared to 10 articles on an average week.Search Interest6 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows3 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $43,476.00 in company stock.Percentage Held by Insiders2.50% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NKTR Stock News HeadlinesNektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its CaseOctober 12 at 1:56 PM | finance.yahoo.comNektar Therapeutics (NASDAQ:NKTR) Stock Picked Up by Analysts at Raymond James FinancialOctober 11 at 1:48 AM | americanbankingnews.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 12 at 1:00 AM | Investors Alley (Ad)Raymond James initiates coverage of Nektar Therapeutics at market performOctober 10 at 12:12 PM | msn.comRaymond James initiates coverage of Nektar Therapeutics with market performOctober 9 at 12:35 AM | msn.com3 ‘Strong Buy’ High-Risk/High-Reward Stocks to Bank on for 100%+ Upside PotentialOctober 9 at 12:31 PM | tipranks.comB. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)October 4, 2026 | theglobeandmail.comNektar Therapeutics (NASDAQ:NKTR) Earns "Buy" Rating from HC WainwrightOctober 4, 2026 | americanbankingnews.comSee More Headlines NKTR Stock Analysis - Frequently Asked Questions How have NKTR shares performed this year? Nektar Therapeutics' stock was trading at $42.28 at the start of the year. Since then, NKTR stock has decreased by 5.8% and is now trading at $39.84. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) released its earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($1.23) EPS for the quarter, beating analysts' consensus estimates of ($1.97) by $0.74. The biopharmaceutical company had revenue of $10.13 million for the quarter, compared to analysts' expectations of $10.43 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 37.87% and a negative net margin of 287.84%. Read the conference call transcript. When did Nektar Therapeutics' stock split? Nektar Therapeutics shares reverse split on Monday, June 9th 2025.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Nektar Therapeutics' major shareholders? Top institutional shareholders of Nektar Therapeutics include Two Seas Capital LP (9.80%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Mark Andrew Wilson, Robert Chess and Jonathan Zalevsky. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Bristol Myers Squibb (BMY), Netflix (NFLX) and ExxonMobil (XOM). Company Calendar Last Earnings8/13/2026Today10/12/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, NKTR's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NKTR CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees63Year Founded1990Price Target and Rating Average Price Target for Nektar Therapeutics$130.67 High Price Target$192.00 Low Price Target$50.00 Potential Upside/Downside+228.0%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($6.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$164.08 million Net Margins-287.84% Pretax Margin-280.48% Return on Equity-37.87% Return on Assets-25.67% Debt Debt-to-Equity RatioN/A Current Ratio10.42 Quick Ratio10.42 Sales & Book Value Annual Sales$55.23 million Price / Sales24.63 Cash FlowN/A Price / Cash FlowN/A Book Value$4.41 per share Price / Book9.03Miscellaneous Outstanding Shares34,140,000Free Float33,289,000Market Cap$1.36 billion OptionableOptionable Beta1.26 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:NKTR) was last updated on 10/12/2026 by MarketBeat.com Staff. From Our PartnersPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredThe AI Stock to Keep an Eye on Before Election Day (See Why)In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...Prosperity Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredTrump To Relaunch USD?President Trump's summit with Xi Jinping drew headlines for tariffs and trade truces, but the real story may b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
